BioPharma Resources

Investigational drug · Phase 3

Exa-cel

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

7

Any phase or sponsor naming "Exa-cel"

First trial start

2018

Nov 27, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Exa-cel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Sickle Cell Disease
  • Hematological Diseases
  • Hemoglobinopathies

Approved drugs for the same conditions: Sickle cell disease · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Exa-cel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 30 on PubMed

Also in development for Sickle Cell Disease

  • FT-4202EtavopivatPhase 36 trials

    Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia

  • IMR-687Tovinontrine, CRD-750Phase 23 trials

    Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases

  • TebapivatAG-946Phase 22 trials

    Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease

  • AnumigilimabPhase 21 trial

    CSL Behring · Sickle Cell Disease

  • BEAM-101Phase 21 trial

    Beam Therapeutics Inc. · Sickle Cell Disease

  • ITU512Phase 21 trial

    Novartis · Sickle Cell Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.